Physician profile
Jonathan Klein
NPI 1326060856
$3,965.77
in general payments reported to CMS, 2019-2025
35 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $287 · 2021: $711 · 2022: $688 · 2023: $853 · 2024: $349 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $787.88 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $365.19 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $258.79 | 2020-2024 | Acthar |
| Glaxosmithkline, LLC. | $238.15 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $231.23 | 2019-2024 | Rybelsus, Ozempic |
| Vifor Pharma, INC. | $215.60 | 2019-2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $214.64 | 2019-2024 | Jynarque, Rexulti |
| Amgen INC. | $207.84 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.42 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $113.60 | 2022-2025 | |
| Esperion Therapeutics, INC. | $96.24 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $91.96 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Mallinckrodt Enterprises LLC | $90.14 | 2019 | |
| Azurity Pharmaceuticals, INC. | $88.31 | 2023 | Edarbi |
| Akebia Therapeutics INC | $81.12 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.18 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $66.72 | 2022 | |
| Eisai INC. | $60.80 | 2021-2022 | |
| Astellas Pharma US INC | $55.27 | 2019-2023 | Veozah |
| Travere Therapeutics, INC. | $42.83 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $41.76 | 2019-2021 | |
| Ucb, INC. | $38.74 | 2021 | |
| Aurinia Pharma U.S., INC. | $38.04 | 2023 | Lupkynis |
| Abbott Laboratories | $37.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $34.88 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $29.05 | 2020-2021 | |
| Becton, Dickinson and Company | $25.00 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.06 | 2023 | |
| Mylan Specialty L.P. | $19.04 | 2024 | Yupelri |
| Fresenius USA Marketing, INC. | $18.66 | 2019 | |
| Biogen, INC. | $17.96 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.96 | 2021 | |
| Acadia Pharmaceuticals INC | $15.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.40 | 2019 | |
| Endo Pharmaceuticals INC. | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.